Copmarison of ensitrelvir and nirmatrelvir/ritonavir

ABSTRACT

ConditionCOVID-19
COVID-19;C01.748.610.763.500;COVID-19

InterventionCOVID-19 patients are randomly assigned (11) to either ensitrelvir or nirmatrelvir/ritonavir. Efficacy of the two medications are assessed.

Primary outcome:five symptoms 5 or 6 days after starting medications

CriteriaInclusion criteria 1.18 years old or more
2.Antigen or PCR test positive for SARS-CoV-2
3.0-3 days after symptom onset
4.Having risk factors of severe COVID-19
5.Written informed consent is obtained

Exclusion criteria 1.Severe adverse events by ensitrelvir or nirmatrelvir/ritonavir
2.Severe kidney failure (eGFR < 30 mL/min)
3.Taking contraindicated medications with ensitrelvir or nirmatrelvir/ritonavir
4.Regarded as inappropriate by study investigators